Stem Cells & Regenerative Medicine
The ability of stem cells to self-renew and give rise to subsequent generations with variable degrees of differentiation capacities, offers significant potential for generation of tissues that can potentially replace diseased and damaged areas in the body, with minimal risk of rejection and side effects. Keeping in view the therapeutic applications of these cells, the DBT has identified this area as one of its thrust areas since 2001.
The overall aim is to promote basic, early and late translational research in the area of stem cell and regenerative medicine and to promote scientific interactions and collaborations amongst clinicians and researchers, building capacity in this area. Scientific strategies includes: basic biology of all adult stem cells, early and late translational research, developing gene editing technology for possible therapeutic applications, creation of animal models for various human diseases and training programmes on various component of stem cells and regenerative medicine.
Outcome of last 5 years
During the last five years, a number of projects have been supported on various aspects of stem cells. The Department has implemented an Indo-Japan collaborative programme to study major brain and blood disorders in Indian population by combining clinical investigations, modern human genetics, and stem cell technology. This programme has a strong training component in iPSc research. Indian researchers and young faculties are being trained at Center for iPSc research and applications (CiRA) at Kyoto University, Japan.
“National Guidelines for Stem Cell Research” jointly formulated by Department of Biotechnology and the Indian Council of Medical Research was released by the Hon’ble Minister for Health & Family Welfare on 11th October; 2017. As per the National Guidelines for Stem Cell Research (2017), at present, there are no approved indications for stem cell therapy other than the hematopoietic stem cell transplantation (HSCT) for hematological disorders. Accordingly, all stem cell therapy other than the above shall be treated as investigational and conducted only in the form of a clinical trial after obtaining necessary regulatory approvals. Use of stem cells for any other purpose outside the domain of clinical trials will be considered unethical and hence is not permissible.
Concerned Officer for more information
|Programme Head||Dr Alka Sharma,Scientist G|
|Programme officer||Dr. Niloo Srivastava, Scientist E|
|Attached officer||Dr. Karthikeya K, Scientist C|